AzTrials
AzTrials

Breast NeoplasmsPhase 3NCT06966700

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

A Phase 3 study testing Sacituzumab tirumotecan, Pembrolizumab and Rescue Medication in people with Breast Neoplasms and Triple Negative Breast Neoplasms, run by Merck Sharp & Dohme LLC at 331 sites in 41 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

Researchers are looking for new ways to treat types of breast cancer that are both: High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Sacituzumab tirumotecan, Pembrolizumab and Rescue Medication
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2,400 participants
Where
331 sitesin 41 countries
Study dates
30 Jun 2025to 29 Dec 2034
Phase
Phase 3

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • The main inclusion criteria include but are not limited to the following:
  • Has previously untreated high-risk, early-stage, non-metastatic (M0) breast cancer (BC), defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per AJCC 8th edition criteria as assessed by the physician investigator based on radiological and/or clinical assessment:
  • cT1c, N1-N2
  • cT2, N0-N2
  • cT3, N0-N2
  • cT4a-d, N0-N2
Show all 10Show fewer
  • The participant must have a centrally confirmed diagnosis of BC that is triple-negative or HR-low+/HER2- (defined as estrogen receptor (ER)-low+ expression in 1% to 10% cells and HER2- as by the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.
  • Provides a core needle biopsy from the primary breast tumor at screening to the central laboratory.
  • Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 28 days before Cycle1 Day 1 (C1D1).
  • Demonstrates adequate organ function.

Who cannot join

  • The main exclusion criteria include but are not limited to the following:
  • Metastatic (Stage IV) breast cancer or clinical node stage 3 (cN3) nodal involvement
  • Has received any prior treatment, including radiation, systemic therapy,and/or definitive surgery for currently diagnosed breast cancer
  • Has undergone excisional biopsy of the primary tumor, axillary lymph node dissection, and/or axillary sentinel lymph node biopsy prior to study treatment.
  • Received prior systemic anticancer therapy including investigational agents within 4 weeks before C1D1.
  • Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX- 40, CD137).
Show all 12Show fewer
  • Received prior treatment with a TROP2-targeted antibody-drug conjugate (ADC).
  • Received prior treatment with a topoisomerase I inhibitor-containing ADC.
  • Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
  • Known additional malignancy that is progressing or has required active treatment within the past 5 years.
  • Uncontrolled systemic disease.
  • History of (noninfectious) pneumonitis/interstitial lung disease that required steroids, has current pneumonitis/interstitial lung disease or has suspected interstitial lung disease (ILD) or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening..

Trial locations and contacts

331 sites in 41 countries. Contact the study team or a site near you to ask about taking part.

Toll Free Number contact

1-888-577-8839

Trialsites@msd.com

331 sites in 41 countries

United States64 sites, 64 recruiting

  • Hendrick Medical Center ( Site 0009)

    Abilene, Texas, 79601

    Study Coordinator, 325-670-2000

    Recruiting

  • AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0044)

    Altamonte Springs, Florida, 32701

    Study Coordinator, 407-834-5151

    Recruiting

  • Mercy Medical Center - Baltimore ( Site 0015)

    Baltimore, Maryland, 21202

    Study Coordinator, 410-951-7956

    Recruiting

  • Massachusetts General Hospital Cancer Center ( Site 0091)

    Boston, Massachusetts, 02114

    Study Coordinator, 617-726-5130

    Recruiting

  • Dana Farber Cancer Institute ( Site 0090)

    Boston, Massachusetts, 02215

    Study Coordinator, 617-632-2175

    Recruiting

  • Roy and Patricia Disney Family Cancer Center ( Site 0055)

    Burbank, California, 91505

    Study Coordinator, 818-840-0921

    Recruiting

  • Southern Illinois Hospital Services ( Site 9554)

    Carterville, Illinois, 62918

    Study Coordinator, 618-549-0721

    Recruiting

  • Medical University of South Carolina-Hollings Cancer Center ( Site 0016)

    Charleston, South Carolina, 29425

    Study Coordinator, 843-792-6434

    Recruiting

  • Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027)

    Cincinnati, Ohio, 45220

    Study Coordinator, 513-853-1300

    Recruiting

  • Community Cancer Institute ( Site 0100)

    Clovis, California, 93611

    Study Coordinator, 559-387-1600

    Recruiting

  • Texas Oncology - DFW ( Site 8009)

    Dallas, Texas, 75246

    Study Coordinator, 214-370-1000

    Recruiting

  • UT Southwestern ( Site 0092)

    Dallas, Texas, 75390

    Study Coordinator, 214-648-3111

    Recruiting

  • Intermountain Health Cancer Center Saint Joseph ( Site 0062)

    Denver, Colorado, 80218

    Study Coordinator, 303-318-3434

    Recruiting

  • Rocky Mountain Cancer Centers (RMCC) ( Site 8006)

    Denver, Colorado, 80220

    Study Coordinator, 303-430-2700

    Recruiting

  • Texas Oncology - Northeast Texas ( Site 8002)

    Flower Mound, Texas, 75028

    Study Coordinator, 972-537-4100

    Recruiting

  • Florida Cancer Specialists - South ( Site 7004)

    Fort Myers, Florida, 33901

    Study Coordinator, 239-274-9930

    Recruiting

  • Fort Wayne Medical Oncology and Hematology ( Site 0084)

    Fort Wayne, Indiana, 46804

    Study Coordinator, 260-436-0800

    Recruiting

  • JPS Oncology and Infusion Center ( Site 0083)

    Fort Worth, Texas, 76104

    Study Coordinator, 817-702-8049

    Recruiting

  • Providence Medical Foundation ( Site 0080)

    Fullerton, California, 92835

    Study Coordinator, 714-446-5900

    Recruiting

  • Banner MD Anderson Cancer Center ( Site 0066)

    Gilbert, Arizona, 85234

    Study Coordinator, 480-256-6444

    Recruiting

  • Altru Health System ( Site 0057)

    Grand Forks, North Dakota, 58201

    Study Coordinator, 701-780-5451

    Recruiting

  • Intermountain Health St. Mary's Regional Hospital ( Site 0054)

    Grand Junction, Colorado, 81501

    Study Coordinator, 970-298-7638

    Recruiting

  • St Francis Cancer Center ( Site 0093)

    Greenville, South Carolina, 29607

    Study Coordinator, 864-603-6200

    Recruiting

  • Hackensack Univ Medical Center (HUMC) ( Site 0007)

    Hackensack, New Jersey, 07601

    Study Coordinator, 551-996-5855

    Recruiting

  • Bioresearch Partner ( Site 0072)

    Hialeah, Florida, 33013

    Study Coordinator, 833-489-4968

    Recruiting

  • Kelsey-Seybold Clinic ( Site 0042)

    Houston, Texas, 77025

    Study Coordinator, 713-239-4510

    Recruiting

  • Kelsey-Seybold Clinic ( Site 0088)

    Houston, Texas, 77025

    Study Coordinator, 713-239-4510

    Recruiting

  • Oncology Consultants P.A. ( Site 0073)

    Houston, Texas, 77030

    Study Coordinator, 713-275-3233

    Recruiting

  • Franciscan Health ( Site 0077)

    Indianapolis, Indiana, 46237

    Study Coordinator, 317-528-7060

    Recruiting

  • Mayo Clinic Hospital ( Site 0013)

    Jacksonville, Florida, 32224

    Study Coordinator, 904-953-7290

    Recruiting

  • Saint Luke's Cancer Institute ( Site 0059)

    Kansas City, Missouri, 64111

    Study Coordinator, 816-923-2677

    Recruiting

  • Tennessee Cancer Specialists ( Site 7001)

    Knoxville, Tennessee, 37909

    Study Coordinator, 865-934-5800

    Recruiting

  • Optum Care Cancer Center ( Site 0050)

    Las Vegas, Nevada, 89102

    Study Coordinator, 702-724-8787

    Recruiting

  • Cancer Partners of Nebraska ( Site 0068)

    Lincoln, Nebraska, 68516

    Study Coordinator, 402-327-7363

    Recruiting

  • MemorialCare Health System - Long Beach Medical Center ( Site 9556)

    Long Beach, California, 90806

    Study Coordinator, 652-241-9755

    Recruiting

  • Texas Tech University Health Sciences Center ( Site 0087)

    Lubbock, Texas, 79430

    Study Coordinator, 806-743-4222

    Recruiting

  • University of Wisconsin-Madison ( Site 0024)

    Madison, Wisconsin, 53792

    Study Coordinator, 608-263-0796

    Recruiting

  • Bon Secours Cancer Institute at St. Francis ( Site 0048)

    Midlothian, Virginia, 23114

    Study Coordinator, 804-893-8717

    Recruiting

  • El Camino Hospital Cancer Center ( Site 0096)

    Mountain View, California, 94040

    Study Coordinator, 650-988-8338

    Recruiting

  • Intermountain Medical Center ( Site 0074)

    Murray, Utah, 84107

    Study Coordinator, 801-507-3630

    Recruiting

  • SCRI Oncology Partners ( Site 7005)

    Nashville, Tennessee, 37203

    Study Coordinator, 615-329-7640

    Recruiting

  • Nashville General Hospital ( Site 0017)

    Nashville, Tennessee, 37208

    Study Coordinator, 615-341-4383

    Recruiting

  • Vanderbilt-Ingram Cancer Center ( Site 0038)

    Nashville, Tennessee, 37232

    Study Coordinator, 615-322-2064

    Recruiting

  • Rutgers Cancer Institute of New Jersey ( Site 0076)

    New Brunswick, New Jersey, 08901

    Study Coordinator, 732-253-3939

    Recruiting

  • Ochsner Clinic Foundation ( Site 0021)

    New Orleans, Louisiana, 70121

    Study Coordinator, 866-624-7637

    Recruiting

  • City of Hope Cancer Center - Atlanta ( Site 0102)

    Newnan, Georgia, 30265

    Study Coordinator, 770-400-6000

    Recruiting

  • Hoag Memorial Hospital Presbyterian ( Site 0010)

    Newport Beach, California, 92663

    Study Coordinator, 949-764-4624

    Recruiting

  • Virginia Oncology Associates (VOA) ( Site 8008)

    Norfolk, Virginia, 23502

    Study Coordinator, 844-482-4812

    Recruiting

  • Mayo Clinic Cancer Center ( Site 0034)

    Phoenix, Arizona, 85054

    Study Coordinator, 480-574-2802

    Recruiting

  • Renown Regional Medical Center ( Site 0041)

    Reno, Nevada, 89502

    Study Coordinator, 775-982-4000

    Recruiting

  • Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8005)

    Roanoke, Virginia, 24014

    Study Coordinator, 540-982-0237

    Recruiting

  • Texas Oncology - San Antonio ( Site 8004)

    San Antonio, Texas, 78240

    Study Coordinator, 210-595-5300

    Recruiting

  • Fred Hutchinson Cancer Center ( Site 0069)

    Seattle, Washington, 98109

    Study Coordinator, 855-557-0555

    Recruiting

  • Louisiana State University Health Sciences Shreveport ( Site 0053)

    Shreveport, Louisiana, 71103

    Study Coordinator, 318-626-0000

    Recruiting

  • Avera McKennan Hospital ( Site 0002)

    Sioux Falls, South Dakota, 57105

    Study Coordinator, 605-322-3000

    Recruiting

  • Cancer Care Northwest ( Site 0003)

    Spokane, Washington, 99202

    Study Coordinator, 509-228-1000

    Recruiting

  • Washington University Siteman Cancer Center ( Site 0031)

    St Louis, Missouri, 63110

    Study Coordinator, 314-286-2341

    Recruiting

  • Florida Cancer Specialists - North ( Site 7002)

    St. Petersburg, Florida, 33701

    Study Coordinator, 727-216-1143

    Recruiting

  • Northwest Medical Specialties, PLLC ( Site 0067)

    Tacoma, Washington, 98405

    Study Coordinator, 253-428-8700

    Recruiting

  • Northwest Cancer Specialists (Compass Oncology) ( Site 8010)

    Tigard, Oregon, 97223

    Study Coordinator, 503-280-1223

    Recruiting

  • University of Arizona Cancer Center ( Site 0035)

    Tucson, Arizona, 85719

    Study Coordinator, 520-694-2873

    Recruiting

  • New England Cancer Specialists ( Site 0051)

    Westbrook, Maine, 04092

    Study Coordinator, 207-303-3300

    Recruiting

  • Helios Clinical Research ( Site 0061)

    Whittier, California, 90602

    Study Coordinator, 562-698-6888

    Recruiting

  • Avera Cancer Institute - Yankton ( Site 0089)

    Yankton, South Dakota, 57078

    Study Coordinator, 605-601-1830

    Recruiting

Other trials in United States

China30 sites, 28 recruiting

  • Beijing Cancer Hospital ( Site 2201)

    Beijing, Beijing Municipality, 100142

    Study Coordinator, +8601088121122

    Recruiting

  • The First Hospital Of Jilin University ( Site 2207)

    Changchun, Jilin, 130021

    Study Coordinator, 0431-88786014

    Recruiting

  • Hunan Cancer Hospital ( Site 2232)

    Changsha, Hunan, 410006

    Study Coordinator, +8673188651900

    Recruiting

  • Xiangya Hospital of Central South University ( Site 2225)

    Changsha, Hunan, 410008

    Study Coordinator, 0731-89753015

    Recruiting

  • Deyang City People's Hospital ( Site 2244)

    Deyang, Sichuan, 618099

    Study Coordinator, 0838-2591961

    Recruiting

  • Guangdong Maternity and Child Health Care Hospital ( Site 2251)

    Guangzhou, Guangdong, 511400

    Study Coordinator, +8602039151777

    Recruiting

  • Harbin Medical University Cancer Hospital ( Site 2204)

    Haerbin, Heilongjiang, 150081

    Study Coordinator, 0451-86298104

    Recruiting

  • The Second Affiliated Hospital Zhejiang University School of Medicine ( Site 2212)

    Hangzhou, Zhejiang, 310017

    Study Coordinator, 0571-86992521

    Recruiting

  • Zhejiang Cancer Hospital ( Site 2211)

    Hangzhou, Zhejiang, 310022

    Active, not recruiting

  • Zhejiang Provincial People's Hospital ( Site 2215)

    Hangzhou, Zhejiang, 311599

    Study Coordinator, 0571-87666666

    Recruiting

  • Anhui Provincial Cancer Hospital ( Site 2234)

    Hefei, Anhui, 230031

    Study Coordinator, +8655165327666

    Recruiting

  • Jiangmen Central Hospital ( Site 2243)

    Jiangmen, Guangdong, 529030

    Study Coordinator, 0750-3385319

    Recruiting

  • Jinan Central Hospital ( Site 2249)

    Jinan, Shandong, 250013

    Study Coordinator, 0531-55739999

    Recruiting

  • Shandong Cancer Hospital ( Site 2205)

    Jinan, Shandong, 250117

    Study Coordinator, 0531-87984777

    Recruiting

  • Yunnan Province Cancer Hospital ( Site 2226)

    Kunming, Yunnan, 650118

    Study Coordinator, 13608815577

    Recruiting

  • LinYi Cancer Hospital ( Site 2248)

    Linyi, Shandong, 276034

    Study Coordinator, 0539-8121800

    Recruiting

  • Liuzhou People's Hospital ( Site 2259)

    Liuzhou, Guangxi, 545006

    Study Coordinator, 0772-2662950

    Recruiting

  • The Third Hospital Of Nanchang ( Site 2218)

    Nanchang, Jiangxi, 330025

    Study Coordinator, 0791-86728121

    Recruiting

  • Jiangsu Province Hospital ( Site 2216)

    Nanjing, Jiangsu, 210003

    Completed

  • Nanjing Drum Tower Hospital ( Site 2217)

    Nanjing, Jiangsu, 210008

    Study Coordinator, 025-83105910

    Recruiting

  • Guangxi Medical University Affiliated Tumor Hospital ( Site 2223)

    Nanning, Guangxi, 530201

    Study Coordinator, +8607715308635

    Recruiting

  • The Second People's Hospital of Neijiang ( Site 2242)

    Neijiang, Sichuan, 641099

    Study Coordinator, 0832-2380771

    Recruiting

  • Fudan University Shanghai Cancer Center ( Site 2209)

    Shanghai, Shanghai Municipality, 200000

    Study Coordinator, 021-6417 5590

    Recruiting

  • Xinjiang Medical University Cancer Hospital - Urumqi ( Site 2230)

    Ürümqi, Xinjiang, 830000

    Study Coordinator, 0991-7819086

    Recruiting

  • Wuhan Union Hospital ( Site 2239)

    Wuhan, Hubei, 430000

    Study Coordinator, 027-85726273

    Recruiting

  • Renmin Hospital of Wuhan University ( Site 2236)

    Wuhan, Hubei, 430060

    Study Coordinator, 027-88041911

    Recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University ( Site 2203)

    Xi'an, Shaanxi, 710000

    Study Coordinator, 029-85324421

    Recruiting

  • The First Affiliated hospital of Xiamen University-Breast Surgery ( Site 2224)

    Xiamen, Fujian, 361009

    Study Coordinator, +86 18205962909

    Recruiting

  • Xingtai People's Hospital ( Site 2260)

    Xingtai, Hebei, 054001

    Study Coordinator, 0319-3956056

    Recruiting

  • Henan Cancer Hospital ( Site 2238)

    Zhengzhou, Henan, 450000

    Study Coordinator, 0371-65587295

    Recruiting

Other trials in China

Japan22 sites, 22 recruiting

  • Akita University Hospital ( Site 2302)

    Akita, 010-8543

    Study Coordinator, +81-18-834-1111

    Recruiting

  • Chiba Cancer Center ( Site 2303)

    Chiba, 260-8717

    Study Coordinator, +81-43-264-5431

    Recruiting

  • National Cancer Center Hospital ( Site 2305)

    Chūō, Tokyo, 104-0045

    Study Coordinator, +81-3-3547-5201

    Recruiting

  • Fukushima Medical University Hospital ( Site 2301)

    Fukushima, 960-1295

    Study Coordinator, +81-24-547-1111

    Recruiting

  • Kansai Medical University Hospital ( Site 2317)

    Hirakata, Osaka, 573-1191

    Study Coordinator, +81-72-804-0101

    Recruiting

  • Hiroshima City Hiroshima Citizens Hospital ( Site 2318)

    Hiroshima, 730-8518

    Study Coordinator, +81-82-221-2291

    Recruiting

  • Kanazawa Medical University Hospital ( Site 2321)

    Kahoku-gun, Ishikawa-ken, 920-0293

    Study Coordinator, +81-76-286-3511

    Recruiting

  • Kumamoto Shinto General Hospital ( Site 2322)

    Kumamoto, 862-8655

    Study Coordinator, +81-96-364-6000

    Recruiting

  • Kyoto University Hospital ( Site 2313)

    Kyoto, 606-8507

    Study Coordinator, +81-75-751-4389

    Recruiting

  • National Hospital Organization Shikoku Cancer Center ( Site 2319)

    Matsuyama, Ehime, 791-0280

    Study Coordinator, +81-89-999-1111

    Recruiting

  • Toranomon Hospital ( Site 2307)

    Minato, Tokyo, 105-8470

    Study Coordinator, +81-3-3588-1111

    Recruiting

  • Nagoya City University Hospital ( Site 2310)

    Nagoya, Aichi-ken, 467-8602

    Study Coordinator, +81-52-858-7215

    Recruiting

  • Naha Nishi Clinic ( Site 2320)

    Naha, Okinawa, 901-0154

    Study Coordinator, +81-98-858-5557

    Recruiting

  • Nakagami Hospital ( Site 2323)

    Okinawa, 904-2195

    Study Coordinator, +81-98-939-1300

    Recruiting

  • National Hospital Organization Osaka National Hospital ( Site 2315)

    Osaka, 540-0006

    Study Coordinator, +81-6-6942-1331

    Recruiting

  • Kindai University Hospital ( Site 2316)

    Sakai, Osaka, 590-0197

    Study Coordinator, +81-72-366-0221

    Recruiting

  • National Hospital Organization Hokkaido Cancer Center ( Site 2300)

    Sapporo, Hokkaido, 003-0804

    Study Coordinator, +81-11-811-9111

    Recruiting

  • Showa Medical University Hospital ( Site 2306)

    Shinagawa, Tokyo, 142-8666

    Study Coordinator, +81-3-3784-8000

    Recruiting

  • The University of Osaka Hospital ( Site 2314)

    Suita, Osaka, 565-0871

    Study Coordinator, +81-6-6210-8290

    Recruiting

  • Shizuoka Cancer Center ( Site 2309)

    Sunto-gun, Shizuoka, 411-8777

    Study Coordinator, +81-55-989-5222

    Recruiting

  • Mie University Hospital ( Site 2312)

    Tsu, Mie-ken, 514-8507

    Study Coordinator, +81-59-231-5246

    Recruiting

  • Kanagawa Cancer Center ( Site 2308)

    Yokohama, Kanagawa, 241-8515

    Study Coordinator, +81-45-520-2222

    Recruiting

Other trials in Japan

Canada15 sites, 15 recruiting

  • Royal Victoria Regional Health Centre ( Site 0233)

    Barrie, Ontario, L4M 6M2

    Study Coordinator, 705-728-9802 x43529

    Recruiting

  • Health Sciences North ( Site 0234)

    Greater Sudbury, Ontario, P3E 5J1

    Study Coordinator, 7055237100

    Recruiting

  • Centre Hospitalier de l'Université de Montréal ( Site 0201)

    Montreal, Quebec, H2X 3E4

    Study Coordinator, 5148908000

    Recruiting

  • Jewish General Hospital ( Site 0200)

    Montreal, Quebec, H3T 1E2

    Study Coordinator, 514-340-8222

    Recruiting

  • McGill University Health Centre ( Site 0202)

    Montreal, Quebec, H4A 3J1

    Study Coordinator, 5149341934

    Recruiting

  • Lakeridge Health ( Site 0225)

    Oshawa, Ontario, L1G 2B9

    Study Coordinator, 9055768711

    Recruiting

  • The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0209)

    Ottawa, Ontario, K1H 8L6

    Study Coordinator, 6137377700

    Recruiting

  • CHU de Quebec Universite Laval - Hopital du Saint-Sacrement ( Site 0203)

    Québec, Quebec, G1S 4L8

    Study Coordinator, 4185254444

    Recruiting

  • Sault Area Hospital ( Site 0226)

    Sault Ste. Marie, Ontario, P6B 0A8

    Study Coordinator, 705-759-3434

    Recruiting

  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0206)

    Sherbrooke, Quebec, J1H 5N4

    Study Coordinator, 8193461110

    Recruiting

  • NL Health Services ( Site 0232)

    St. John's, Newfoundland and Labrador, A1B 3V6

    Study Coordinator, 7097772638

    Recruiting

  • BC Cancer - Surrey ( Site 0217)

    Surrey, British Columbia, V3V 1Z2

    Study Coordinator, 604-930-2098

    Recruiting

  • Princess Margaret Cancer Centre ( Site 0208)

    Toronto, Ontario, M5G 2M9

    Study Coordinator, 4169462000

    Recruiting

  • Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 0204)

    Trois-Rivières, Quebec, G8Z 3R9

    Study Coordinator, 8196973333x63238

    Recruiting

  • BC Cancer Vancouver ( Site 0218)

    Vancouver, British Columbia, V5Z 4E6

    Study Coordinator, 604-877-6000

    Recruiting

Other trials in Canada

Italy12 sites, 12 recruiting

  • Azienda Ospedaliero Universitaria delle Marche ( Site 4509)

    Ancona, 60126

    Study Coordinator, +390715965715

    Recruiting

  • ASST Papa Giovanni XXIII ( Site 4511)

    Bergamo, 24127

    Study Coordinator, +390352674366

    Recruiting

  • IRCCS Azienda Ospedaliera Metropolitana ( Site 4508)

    Genova, 16132

    Study Coordinator, +390105558908

    Recruiting

  • Azienda USL Toscana Nord Ovest_Ospedale Civile di Livorno ( Site 4503)

    Livorno, Tuscany, 57124

    Study Coordinator, +39 0586223416

    Recruiting

  • Ospedale San Raffaele di Milano ( Site 4515)

    Milan, 20132

    Study Coordinator, 390226436530

    Recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 4501)

    Milan, 20133

    Study Coordinator, +390223905000

    Recruiting

  • Fondazione IRCCS San Gerardo dei Tintori ( Site 4513)

    Monza, Lombardy, 20900

    Study Coordinator, 00390392339037

    Recruiting

  • Istituto Oncologico Veneto IRCCS ( Site 4505)

    Padova, 35128

    Study Coordinator, +39 049 - 821 1111

    Recruiting

  • Azienda Ospedaliero Universitaria Pisana ( Site 4506)

    Pisa, 56126

    Study Coordinator, +39050992371

    Recruiting

  • Arcispedale Santa Maria Nuova ( Site 4510)

    Reggio Emilia, 42123

    Study Coordinator, +39 0522 295718

    Recruiting

  • Istituto Nazionale Tumori Regina Elena ( Site 4512)

    Roma, 00144

    Study Coordinator, +39 06 52666919

    Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 4500)

    Roma, 00168

    Study Coordinator, +390630158545

    Recruiting

Other trials in Italy

Brazil10 sites, 10 recruiting

  • Fundação Pio XII - Hospital de Câncer de Barretos ( Site 6108)

    Barretos, São Paulo, 14784-400

    Study Coordinator, +551733216637

    Recruiting

  • Clínica de Oncologia Reichow ( Site 6112)

    Blumenau, Santa Catarina, 89010-340

    Study Coordinator, +554733805890

    Recruiting

  • PRONUTRIR ( Site 6120)

    Fortaleza, Ceará, 60810-180

    Study Coordinator, +558532865934

    Recruiting

  • Hospital Araújo Jorge ( Site 6100)

    Goiânia, Goiás, 74605-070

    Study Coordinator, +556232437260

    Recruiting

  • Liga Norte Riograndense Contra o Câncer ( Site 6111)

    Natal, Rio Grande do Norte, 59062-000

    Study Coordinator, +558440095595

    Recruiting

  • Associação Hospitalar Beneficente São Vicente de Paulo ( Site 6115)

    Passo Fundo, Rio Grande do Sul, 99010-080

    Study Coordinator, +555421033490

    Recruiting

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 6102)

    Porto Alegre, Rio Grande do Sul, 90035-074

    Study Coordinator, +5551997292010

    Recruiting

  • Hospital São Lucas da PUCRS ( Site 6103)

    Porto Alegre, Rio Grande do Sul, 90610-000

    Study Coordinator, +555133203039

    Recruiting

  • INCA Hospital do Câncer III ( Site 6107)

    Rio de Janeiro, 20560-120

    Study Coordinator, +552132073810

    Recruiting

  • Hospital de Base de São José do Rio Preto ( Site 6101)

    São José do Rio Preto, São Paulo, 15090-000

    Study Coordinator, +551732015054

    Recruiting

Other trials in Brazil

Poland10 sites, 10 recruiting

  • Bialostockie Centrum Onkologii im.M.Sklodowskiej-Curie ( Site 4608)

    Bialystok, Podlaskie Voivodeship, 15-027

    Study Coordinator, +48856646888

    Recruiting

  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 4616)

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796

    Study Coordinator, +48523743525

    Recruiting

  • Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 4619)

    Kielce, Świętokrzyskie Voivodeship, 25-734

    Study Coordinator, +48413674315

    Recruiting

  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie ( Site 4611)

    Koszalin, West Pomeranian Voivodeship, 75-581

    Study Coordinator, +48502204953

    Recruiting

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Oddzial w Krakowie ( Site 4612)

    Krakow, Lesser Poland Voivodeship, 31-115

    Study Coordinator, +48225462758

    Recruiting

  • Salve Medica sp. z o.o. sp. k. ( Site 4618)

    Lodz, Łódź Voivodeship, 91-211

    Study Coordinator, +48422546440

    Recruiting

  • Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onko ( Site 4614)

    Olsztyn, Warmian-Masurian Voivodeship, 10-228

    Study Coordinator, +48895398078

    Recruiting

  • Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 4600)

    Słupsk, Pomeranian Voivodeship, 76-200

    Study Coordinator, +48598460450

    Recruiting

  • Specjalistyczny Szpital im. dra A. Sokolowskiego w Walbrzychu ( Site 4604)

    Wałbrzych, Lower Silesian Voivodeship, 58-309

    Study Coordinator, +48746489736

    Recruiting

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 4609)

    Warsaw, Masovian Voivodeship, 02-781

    Study Coordinator, +48225462486

    Recruiting

Other trials in Poland

Spain10 sites, 10 recruiting

  • Parc de Salut Mar - Hospital del Mar ( Site 5005)

    Barcelona, 08003

    Study Coordinator, +34932483860

    Recruiting

  • Hospital de Basurto ( Site 5007)

    Bilbao, Bizkaia, 48013

    Study Coordinator, +34944006367

    Recruiting

  • HOSPITAL UNIVERSITARIO DE JAEN ( Site 5003)

    Jaén, Jaen, 23007

    Study Coordinator, +34953220306

    Recruiting

  • Institut Català d'Oncologia - L'Hospitalet ( Site 5001)

    L'Hospitalet de Llobregat, Barcelona, 08908

    Study Coordinator, +34932607283

    Recruiting

  • Hospital Beata María Ana ( Site 5010)

    Madrid, +34914097423

    Study Coordinator, + 34 914097423

    Recruiting

  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 5004)

    Pozuelo de Alarcón, Madrid, 28223

    Study Coordinator, +34914521987

    Recruiting

  • Complejo asistencial universitario de Salamanca ( Site 5000)

    Salamanca, Castille and León, 37007

    Study Coordinator, +34923291100X55749

    Recruiting

  • CHUS - Hospital Clinico Universitario ( Site 5006)

    Santiago de Compostela, La Coruna, 19706

    Study Coordinator, +34 663609134

    Recruiting

  • Hospital Universitario Virgen Macarena ( Site 5002)

    Seville, 41009

    Study Coordinator, +34955008000

    Recruiting

  • Hospital General de Valencia ( Site 5008)

    Valencia, Valenciana, Comunitat, 46014

    Study Coordinator, +34963131800-437639

    Recruiting

Other trials in Spain

Argentina9 sites, 9 recruiting

  • Hospital Italiano de Buenos Aires-ginecology ( Site 6003)

    Buenos Aires, Buenos Aires F.D., C1199ABB

    Study Coordinator, +541149584546

    Recruiting

  • Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 6005)

    Buenos Aires, Buenos Aires F.D., C1431FWO

    Study Coordinator, +549 1152990000

    Recruiting

  • Sanatorio Finochietto ( Site 6007)

    Buenos Aires, C1187AAN

    Study Coordinator, +54 11 58216233

    Recruiting

  • Sanatorio Allende - Nueva Córdoba ( Site 6000)

    Córdoba, X5000BFB

    Study Coordinator, 08105552553

    Recruiting

  • Sanatorio de la Cañada - Córdoba ( Site 6001)

    Córdoba, X5000BSQ

    Study Coordinator, 08101225800

    Recruiting

  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 6008)

    Mar del Plata, Buenos Aires, B7600FZO

    Study Coordinator, +542234963224

    Recruiting

  • Sanatorio Parque ( Site 6002)

    Rosario, Santa Fe Province, S2000DSV

    Study Coordinator, +5493416955611

    Recruiting

  • Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L ( Site 6006)

    San Miguel de Tucumán, Tucumán Province, T4000IHE

    Study Coordinator, +543814502600

    Recruiting

  • Fundacion Ars Medica ( Site 6004)

    San Salvador de Jujuy, Jujuy Province, Y4600EHA

    Study Coordinator, +54 3884315604

    Recruiting

Other trials in Argentina

France9 sites, 9 recruiting

  • CHU d'Amiens-Picardie - Hôpital Sud ( Site 3908)

    Amiens, Somme, 80054

    Study Coordinator, 0033322088000

    Recruiting

  • HENRI MONDOR HOSPITAL ( Site 3904)

    Créteil, Val-de-Marne, 94010

    Study Coordinator, 0033149812567

    Recruiting

  • Centre Georges Francois Leclerc ( Site 3902)

    Dijon, Bourgogne-Franche-Comté, 21000

    Study Coordinator, +33345348051

    Recruiting

  • Institut Paoli Calmettes. ( Site 3906)

    Marseille, Bouches-du-Rhone, 13009

    Study Coordinator, +33491223537

    Recruiting

  • Centre de Cancerologie du Grand Montpellier ( Site 3910)

    Montpellier, Herault, 34070

    Study Coordinator, +33430298723

    Recruiting

  • Institut Curie ( Site 3903)

    Paris, 75248

    Study Coordinator, +33144324685

    Recruiting

  • centre hospitalier lyon sud ( Site 3901)

    Pierre-Bénite, Rhone, 69310

    Study Coordinator, +33478864324

    Recruiting

  • Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 3900)

    Rennes, Ille-et-Vilaine, 35000

    Study Coordinator, +33299253280

    Recruiting

  • Institut Curie - site Saint-Cloud ( Site 3909)

    Saint-Cloud, Hauts-de-Seine, 92210

    Study Coordinator, +33144324685

    Recruiting

Other trials in France

Turkey (Türkiye)9 sites, 9 recruiting

  • Basken Adana Dr.Turgut Noyan Uygulama ve Arastirma Merkezi. ( Site 5112)

    Adana, 01250

    Study Coordinator, +0905353067506

    Recruiting

  • Memorial Ankara Hastanesi ( Site 5116)

    Ankara, 06520

    Study Coordinator, +903122536666

    Recruiting

  • Ankara Bilkent Şehir Hastanesi. ( Site 5114)

    Ankara, 06800

    Study Coordinator, +903125526000

    Recruiting

  • I.U. Cerrahpasa Medical Faculty ( Site 5111)

    Istanbul, 34098

    Study Coordinator, +0905324167355

    Recruiting

  • Bakirkoy Dr. Sadi Konuk Training and Research Hospital ( Site 5117)

    Istanbul, 34147

    Study Coordinator, +902124147171

    Recruiting

  • Erciyes University ( Site 5119)

    Kayseri, 38039

    Study Coordinator, +90 (352) 207 66 66

    Recruiting

  • Mersin Sehir Eğitim ve Araştırma Hastanesi ( Site 5123)

    Mersin, 33240

    Study Coordinator, +903242251000

    Recruiting

  • Samsun Medical Park Hastanesi ( Site 5121)

    Samsun, 55200

    Study Coordinator, +90 362 311 40 40

    Recruiting

  • Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 5110)

    Sıhhiye, Ankara, 06230

    Study Coordinator, +903123052935

    Recruiting

Other trials in Turkey (Türkiye)

United Kingdom9 sites, 9 recruiting

  • Blackpool Victoria Hospital ( Site 5310)

    Blackpool, FY3 8NR

    Study Coordinator

    Recruiting

  • Colchester General Hospital ( Site 5307)

    Colchester, Essex, CO4 5JL

    Study Coordinator

    Recruiting

  • Ninewells Hospital and Medical School ( Site 5300)

    Dundee, Dundee City, DD2 1SG

    Study Coordinator, +441382660111

    Recruiting

  • Huddersfield Royal Infirmary ( Site 5313)

    Huddersfield, England, HD3 3EA

    Study Coordinator, +441484347100

    Recruiting

  • Leicester Royal Infirmary ( Site 5309)

    Leicester, LE1 5WW

    Study Coordinator, +44116 258 6295

    Recruiting

  • University College London Hospital ( Site 5301)

    London, Camden, NW1 2PG

    Study Coordinator, 02034567890

    Recruiting

  • St Bartholomew s Hospital ( Site 5302)

    London, London, City of, EC1A 7BE

    Study Coordinator, +442073777000

    Recruiting

  • Nottingham University Hospitals NHS Trust ( Site 5314)

    Nottingham, Nottinghamshire, NG5 1PB

    Study Coordinator

    Recruiting

  • Princess Royal University Hospital ( Site 5316)

    Orpington, Kent, BR6 8ND

    Study Coordinator, +441689864042

    Recruiting

Other trials in United Kingdom

South Korea8 sites, 8 recruiting

  • National Cancer Center ( Site 1800)

    Goyang-si, Kyonggi-do, 10408

    Study Coordinator, +82319200396

    Recruiting

  • Seoul National University Bundang Hospital ( Site 1801)

    Kyonggi-do, Kyonggi-do, 13620

    Study Coordinator, +82317873942

    Recruiting

  • Seoul National University Hospital ( Site 1806)

    Seoul, 03080

    Study Coordinator, 82220720795

    Recruiting

  • Severance Hospital Yonsei University Health System ( Site 1804)

    Seoul, 03722

    Study Coordinator, +82222288135

    Recruiting

  • Asan Medical Center ( Site 1803)

    Seoul, 05505

    Study Coordinator, +82230103215

    Recruiting

  • Samsung Medical Center ( Site 1807)

    Seoul, 06351

    Study Coordinator, 82234106488

    Recruiting

  • The Catholic University of Korea. Seoul St. Mary s Hospital ( Site 1802)

    Seoul, 06591

    Study Coordinator, 8222586048

    Recruiting

  • Kyungpook National University Chilgok Hospital ( Site 1805)

    Taegu, Taegu-Kwangyokshi, 41404

    Study Coordinator, 82532002624

    Recruiting

Other trials in South Korea

Peru7 sites, 7 recruiting

  • Instituto Regional de Enfermedades Neoplasicas del Centro (IREN CENTRO) ( Site 6605)

    Concepción, Departamento de Junín, 12125

    Study Coordinator, +51 958 864 658

    Recruiting

  • Hospital Guillermo Almenara Irigoyen ( Site 6601)

    Lima, 15001

    Study Coordinator, +51 999 903 343

    Recruiting

  • IPOR Instituto Peruano de Oncología & Radioterapia ( Site 6600)

    Lima, 15036

    Study Coordinator, 6600

    Recruiting

  • Oncosalud ( Site 6603)

    Lima, 15036

    Study Coordinator, +51957511783

    Recruiting

  • Hospital Nacional Edgardo Rebagliati Martins ( Site 6602)

    Lima, 15072

    Study Coordinator, +51012654901 3393

    Recruiting

  • INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 6604)

    Surquillo, Muni Metro de Lima, 15038

    Study Coordinator, +51938707205

    Recruiting

  • Instituto Regional de Enfermedades Neoplásicas Del Norte ( Site 6606)

    Trujillo, La Libertad, 13001

    Study Coordinator, +51948318825

    Recruiting

Other trials in Peru

Colombia6 sites, 6 recruiting

  • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 6311)

    Bogotá, Bogota D.C., 110131

    Study Coordinator, +57 3174236866

    Recruiting

  • Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 6309)

    Bogotá, Bogota D.C., 111321

    Study Coordinator, +57 3125901340

    Recruiting

  • Fundación Valle del Lili ( Site 6308)

    Cali, Valle del Cauca Department, 760032

    Study Coordinator, +57 6023319090

    Recruiting

  • Promotora Médica Las Américas S.A. ( Site 6302)

    Medellín, Antioquia, 050025

    Study Coordinator, +576043409393

    Recruiting

  • IMAT S.A.S ( Site 6300)

    Montería, Departamento de Córdoba, 230002

    Study Coordinator, +573135342052

    Recruiting

  • Oncologos del Occidente ( Site 6303)

    Pereira, Risaralda Department, 660001

    Study Coordinator, +573154208077

    Recruiting

Other trials in Colombia

Germany6 sites, 6 recruiting

  • Helios Klinikum Berlin-Buch ( Site 4008)

    Berlin, 13125

    Study Coordinator, +4930940153300

    Recruiting

  • Universitaetsklinik Erlangen ( Site 4001)

    Erlangen, Bavaria, 91054

    Study Coordinator, +499131 8536895

    Recruiting

  • InVO Institut für Versorgungsforschung in der Onkologie ( Site 4009)

    Koblenz, Rhineland-Palatinate, 56068

    Study Coordinator, +49261921569323

    Recruiting

  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen ( Site 4015)

    Munich, Bavaria, 80336

    Study Coordinator, +4989440034645

    Recruiting

  • St. Vincenz-Krankenhaus Frauen- und Kinderklinik ( Site 4003)

    Paderborn, North Rhine-Westphalia, 33098

    Study Coordinator, +495251864121

    Recruiting

  • CaritasKlinikum Saarbruecken St. Theresia ( Site 4014)

    Saarbrücken, Saarland, 66113

    Study Coordinator, +496814061345

    Recruiting

Other trials in Germany

Guatemala6 sites, 5 recruiting

  • MEDI-K ( Site 6400)

    Guatemala City, 01009

    Study Coordinator, +50222912323

    Recruiting

  • CELAN,S.A ( Site 6401)

    Guatemala City, 01010

    Study Coordinator, +50222968018

    Recruiting

  • INTEGRA Cancer Institute ( Site 6404)

    Guatemala City, 01010

    Study Coordinator, +50222790939

    Recruiting

  • Onco Go, S.A ( Site 6402)

    Guatemala City, 01010

    Study Coordinator, +50223723601

    Recruiting

  • Oncomedica ( Site 6405)

    Guatemala City, 01010

    Study Coordinator, +50224484549

    Recruiting

  • Asociacion Española de Beneficencia ( Site 6403)

    Guatemala City, 01015

    Active, not recruiting

Other trials in Guatemala

Belgium5 sites, 5 recruiting

  • AZORG Campus Aalst-Moorselbaan ( Site 3201)

    Aalst, Oost-Vlaanderen, 9300

    Study Coordinator, +3253724111

    Recruiting

  • UZ Gent ( Site 3202)

    Ghent, Oost-Vlaanderen, 9000

    Study Coordinator, +3293322692

    Recruiting

  • Jessa Ziekenhuis ( Site 3200)

    Hasselt, Limburg, 3500

    Study Coordinator, +32 11 33 79 92

    Recruiting

  • Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman ( Site 3204)

    Liège, Liege, 4000

    Study Coordinator, +3243232311

    Recruiting

  • CHU UCL Namur/Site Sainte Elisabeth ( Site 3203)

    Namur, 5000

    Study Coordinator, +3281720547

    Recruiting

Other trials in Belgium

Greece5 sites, 5 recruiting

  • General Hospital of Athens - Laiko ( Site 4104)

    Athens, Attica, 115 27

    Study Coordinator, +306944681159

    Recruiting

  • Aretaieio Hospital Oncology Unit ( Site 4101)

    Athens, Attica, 115 28

    Study Coordinator, +302107286305

    Recruiting

  • Metropolitan Hospital ( Site 4102)

    Athens, Attica, 185 47

    Study Coordinator, +302104809339

    Recruiting

  • ATHENS MEDICAL CENTER ( Site 4100)

    Marousi, Attica, 151 25

    Study Coordinator, 0030 2107464642

    Recruiting

  • European Interbalkan Medical Center ( Site 4103)

    Thessaloniki, 570 01

    Study Coordinator, 0030 2310400213

    Recruiting

Other trials in Greece

Hungary5 sites, 5 recruiting

  • Országos Onkológiai Intézet-B-Belgyógyászati Onkológiai Osztály ( Site 4204)

    Budapest, 1122

    Study Coordinator, +3612248600

    Recruiting

  • Bacs-Kiskun Varmegyei Oktatokorhaz-Onkoradiologiai Kozpont ( Site 4207)

    Kecskemét, Bács-Kiskun county, 6000

    Study Coordinator, +3676516719

    Recruiting

  • Borsod-Abaúj-Zemplén Vármegyei Központi Kórház És Egyetemi Oktatókórház ( Site 4208)

    Miskolc, Borsod-Abauj Zemplen county, 3526

    Study Coordinator, +36 20-410-8060

    Recruiting

  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Onkoterapias Klinika ( Site 4202)

    Szeged, Csongrád megye, 6720

    Study Coordinator, +3662545404

    Recruiting

  • Zala Vármegyei Szent Rafael Kórház-Onkológiai osztály ( Site 4206)

    Zalaegerszeg, Zala County, 8900

    Study Coordinator, +36304199969

    Recruiting

Other trials in Hungary

Malaysia5 sites, 5 recruiting

  • Hospital Pulau Pinang ( Site 1502)

    George Town, Pulau Pinang, 10450

    Study Coordinator, +604-2225333

    Recruiting

  • Pantai Hospital Kuala Lumpur ( Site 1500)

    Kuala Lumpur, 59100

    Study Coordinator, +603-2296 0888

    Recruiting

  • Sarawak General Hospital ( Site 1504)

    Kuching, Sarawak, 93586

    Study Coordinator, +60182327023

    Recruiting

  • University Malaya Medical Centre. ( Site 1503)

    Lembah Pantai, Kuala Lumpur, 59100

    Study Coordinator, +6014-9337966

    Recruiting

  • National Cancer Institute ( Site 1501)

    Putrajaya, Putrajaya, 62250

    Study Coordinator, +60124332344

    Recruiting

Other trials in Malaysia

Romania5 sites, 5 recruiting

  • Spitalul Clinic Filantropia ( Site 4801)

    Bucharest, 011132

    Study Coordinator, +40213188930

    Recruiting

  • SC Radiotherapy Center Cluj SRL ( Site 4808)

    Cluj-Napoca, Cluj, 407280

    Study Coordinator, 40742206212

    Recruiting

  • Institutul Oncologic Cluj ( Site 4802)

    Cluj-Napoca, 400015

    Study Coordinator, +40264598362

    Recruiting

  • Institutul Regional de Oncologie ( Site 4805)

    Iași, 700483

    Study Coordinator, +40751193788

    Recruiting

  • Cabinet Medical Oncomed ( Site 4803)

    Timișoara, Timiș County, 300239

    Study Coordinator, +40256495403

    Recruiting

Other trials in Romania

South Africa5 sites, 5 recruiting

  • Cancercare Rondebosch Oncology ( Site 4906)

    Cape Town, Western Cape, 7700

    Study Coordinator, 27(0)21 9443700

    Recruiting

  • Wits Clinical Research ( Site 4903)

    Johannesburg, Gauteng, 2193

    Study Coordinator, 27113390600

    Recruiting

  • CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 4907)

    Port Elizabeth, Eastern Cape, 6045

    Study Coordinator, +27413630218

    Recruiting

  • LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 4901)

    Pretoria, Gauteng, 0181

    Study Coordinator, 27123466701

    Recruiting

  • Sandton Oncology Medical Group (Pty) Ltd ( Site 4900)

    Sandton, Gauteng, 2196

    Study Coordinator, 27118830900

    Recruiting

Other trials in South Africa

Taiwan5 sites, 5 recruiting

  • Taichung Veterans General Hospital ( Site 1904)

    Taichung, 407

    Study Coordinator, 886423592525x5031

    Recruiting

  • National Taiwan University Hospital ( Site 1900)

    Taipei, 10048

    Study Coordinator, +88623123456x71673

    Recruiting

  • MacKay Memorial Hospital ( Site 1903)

    Taipei, 10449

    Study Coordinator, +886-975835311

    Recruiting

  • National Taiwan University Cancer Center (NTUCC) ( Site 1901)

    Taipei, 106

    Study Coordinator, +886-223123456x65422

    Recruiting

  • Chang Gung Medical Foundation-Linkou Branch ( Site 1906)

    Taoyuan, 33305

    Study Coordinator, +88633281200x3219

    Recruiting

Other trials in Taiwan

Ukraine5 sites, 5 recruiting

  • COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 5207)

    Cherkasy, Cherkasy Oblast, 18009

    Study Coordinator, +380472319418

    Recruiting

  • Municipal Enterprise "Bukovinian сlinical oncology сenter" ( Site 5208)

    Chernivtsi, Chernivetska Oblast, 58013

    Study Coordinator, 380955077568

    Recruiting

  • CNCE Precarpathian Clinical Oncologic Center ( Site 5201)

    Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76018

    Study Coordinator, +380342759071

    Recruiting

  • CNE Regional clinical oncology center of Kirovograd regional Council ( Site 5203)

    Kropyvnytsky, Kirovohrad Oblast, 25011

    Study Coordinator, +380508427973

    Recruiting

  • Shalimov Institute of Surgery and Transplantation ( Site 5210)

    Kyiv, 03126

    Study Coordinator, +380939720596

    Recruiting

Other trials in Ukraine

Australia4 sites, 4 recruiting

  • Chris O'Brien Lifehouse ( Site 1206)

    Camperdown, New South Wales, 2050

    Study Coordinator, 61 02 8514 0000

    Recruiting

  • Monash Health ( Site 1201)

    Clayton, Victoria, 3168

    Study Coordinator, 61 3 8572 5402

    Recruiting

  • Macquarie University ( Site 1203)

    North Ryde, New South Wales, 2109

    Study Coordinator, 61 02 9812 2956

    Recruiting

  • Westmead Hospital ( Site 1200)

    Westmead, New South Wales, 2145

    Study Coordinator, 61 2 8890 6728

    Recruiting

Other trials in Australia

Chile4 sites, 4 recruiting

  • Centro de Estudios Clínicos SAGA ( Site 6205)

    Santiago, Region M. de Santiago, 7500653

    Study Coordinator, 56991612199

    Recruiting

  • Fundación Arturo López Pérez ( Site 6200)

    Santiago, Region M. de Santiago, 7500921

    Study Coordinator, +56224457398

    Recruiting

  • Bradfordhill ( Site 6202)

    Santiago, Region M. de Santiago, 8420383

    Study Coordinator, 56229490970

    Recruiting

  • ONCOCENTRO APYS ( Site 6204)

    Viña del Mar, Valparaiso, 2520598

    Study Coordinator, +56323320850

    Recruiting

Other trials in Chile

Czechia4 sites, 4 recruiting

  • Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 3400)

    Brno, Brno-mesto, 656 53

    Study Coordinator, +420543134000

    Recruiting

  • Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie ( Site 3403)

    Hradec Králové, 500 05

    Study Coordinator, +420495834851

    Recruiting

  • Krajska nemocnice Liberec a.s.-Komplexni onkologicke centrum ( Site 3404)

    Liberec, 460 01

    Study Coordinator, +420485312259

    Recruiting

  • Nemocnice AGEL Novy Jicin a.s.-Oddeleni radioterapie a onkologie ( Site 3401)

    Nový Jičín, Moravian-Silesian Region, 741 01

    Study Coordinator, +420556416180

    Recruiting

Other trials in Czechia

Hong Kong4 sites, 4 recruiting

  • Hong Kong United Oncology Centre ( Site 1304)

    Jordan

    Study Coordinator, +852 2386 8002

    Recruiting

  • Queen Mary Hospital ( Site 1300)

    Pokfulam

    Study Coordinator, 85239103299

    Recruiting

  • Prince of Wales Hospital ( Site 1301)

    Shatin

    Study Coordinator, +852 3505 3555

    Recruiting

  • Tuen Mun Hospital ( Site 1303)

    Tuenmen

    Study Coordinator, +852 2468 5111

    Recruiting

Other trials in Hong Kong

Israel4 sites, 4 recruiting

  • Rambam Health Care Campus ( Site 4400)

    Haifa, 3109601

    Study Coordinator, +97247772688

    Recruiting

  • Meir Medical Center. ( Site 4403)

    Kfar Saba, 4428164

    Study Coordinator, 054-5562339

    Recruiting

  • Sheba Medical Center ( Site 4401)

    Ramat Gan, 5265601

    Study Coordinator, +972-35304436

    Recruiting

  • Yitzhak Shamir Medical Center. ( Site 4404)

    Ẕerifin, 70300

    Study Coordinator, +972-507324996

    Recruiting

Other trials in Israel

Norway4 sites, 4 recruiting

  • Nordlandssykehuset ( Site 3704)

    Bodø, Nordland, 8005

    Study Coordinator, +47 75 53 40 00

    Recruiting

  • Drammen Sykehus, Vestre Viken HF ( Site 3700)

    Drammen, Buskerud, 3004

    Study Coordinator, +4732803000

    Recruiting

  • Akershus Universitetssykehus ( Site 3701)

    Lørenskog, Akershus, 1474

    Study Coordinator, +4767963073

    Recruiting

  • Stavanger Universitetssjukehus ( Site 3702)

    Stavanger, Rogaland, 4011

    Study Coordinator, +4751518000

    Recruiting

Other trials in Norway

Portugal4 sites, 4 recruiting

  • Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 4702)

    Lisbon, Lisbon District, 1449-005

    Study Coordinator, +351210431000

    Recruiting

  • Hospital de Cascais Doutor José de Almeida ( Site 4700)

    Lisbon, 2755-009

    Study Coordinator, +351214653000

    Recruiting

  • Instituto Portugues de Oncologia do Porto ( Site 4705)

    Porto, 4200-072

    Study Coordinator, + 3512250840000

    Recruiting

  • Unidade Local de Saúde de São João ( Site 4703)

    Porto, 4200-319

    Study Coordinator, +351225512100

    Recruiting

Other trials in Portugal

Sweden4 sites, 4 recruiting

  • Södra Älvsborgs Sjukhus Borås ( Site 3804)

    Borås, Västra Götaland County, 501 82

    Study Coordinator, 46336161000

    Recruiting

  • Skånes Universitetssjukhus Malmö ( Site 3802)

    Malmö, Skåne County, 20502

    Study Coordinator, 4640331000

    Recruiting

  • Karolinska Universitetssjukhuset Solna ( Site 3800)

    Stockholm, Stockholm County, 171 64

    Study Coordinator, 0046812370000

    Recruiting

  • Akademiska sjukhuset ( Site 3801)

    Uppsala, Uppsala County, 751 85

    Study Coordinator, 0046186110000

    Recruiting

Other trials in Sweden

Thailand4 sites, 4 recruiting

  • Faculty of Medicine Siriraj Hospital ( Site 2000)

    Bangkok, Bangkok, 10700

    Study Coordinator, +6624192977

    Recruiting

  • Songklanagarind Hospital ( Site 2002)

    Hat Yai, Changwat Songkhla, 90110

    Study Coordinator, +6674282000

    Recruiting

  • Maharaj Nakorn Chiang Mai Hospital ( Site 2003)

    Muang, Chiang Mai, 50200

    Study Coordinator, +6653935533

    Recruiting

  • Chulalongkorn University ( Site 2001)

    Pathumwan, Bangkok, 10330

    Study Coordinator, +6622564533

    Recruiting

Other trials in Thailand

Finland3 sites, 3 recruiting

  • Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 3600)

    Helsinki, Uusimaa, 00029

    Study Coordinator, +358947174900

    Recruiting

  • Oulun yliopistollinen sairaala ( Site 3603)

    Oulu, North Ostrobothnia, 90220

    Study Coordinator, +35886699500

    Recruiting

  • Tampereen ylipistollinen sairaala ( Site 3601)

    Tampere, Pirkanmaa, 33520

    Study Coordinator, +358331165410

    Recruiting

Other trials in Finland

Vietnam3 sites, 3 recruiting

  • Hanoi Oncology Hospital ( Site 2101)

    Hanoi, Hanoi, 100000

    Study Coordinator, +84915546116

    Recruiting

  • K Hospital - National Cancer Hospital ( Site 2100)

    Hanoi, Hanoi, 100000

    Study Coordinator, +84903229187

    Recruiting

  • Oncology Hospital ( Site 2102)

    Ho Chi Minh City, Ho Chi Minh, 700000

    Study Coordinator, +842838412637

    Recruiting

Other trials in Vietnam

New Zealand2 sites, 2 recruiting

  • Auckland City Hospital ( Site 1000)

    Auckland, 1023

    Study Coordinator, +6493074949

    Recruiting

  • Bowen Icon Cancer Centre ( Site 1001)

    Crofton Downs, Wellington Region, 6035

    Study Coordinator, +6448960200

    Recruiting

Other trials in New Zealand

Philippines2 sites, 2 recruiting

  • Makati Medical Center ( Site 1609)

    Makati City, National Capital Region, 1229

    Study Coordinator, +639272648292

    Recruiting

  • THE MEDICAL CITY ( Site 1602)

    Pasig, National Capital Region, 1605

    Study Coordinator, +639176589771

    Recruiting

Other trials in Philippines

India1 site, 1 recruiting

  • Basavatarakam Indo American Cancer Hospital & Research Institute ( Site 1408)

    Hyderabad, Telangana, 500034

    Study Coordinator, +914023550015

    Recruiting

Other trials in India

Saudi Arabia1 site, 1 recruiting

  • King Faisal Specialist Hospital and Research Center ( Site 5400)

    Riyadh, Riyadh Region, 11564

    Study Coordinator, +966114647272

    Recruiting

Other trials in Saudi Arabia

Singapore1 site, 1 recruiting

  • National Cancer Centre Singapore ( Site 1700)

    Singapore, Central Singapore, 168583

    Study Coordinator, +6564368000

    Recruiting

Other trials in Singapore

About this study

Official title: A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Researchers are looking for new ways to treat types of breast cancer that are both:

  • High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment
  • Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone.
Read more

Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread.

The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy:

  • Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy
  • Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy
Being tested
Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel
Keywords
Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1), Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
Medical subject headings
Breast Neoplasms, Triple Negative Breast Neoplasms, Parkinson Disease 4, Autosomal Dominant Lewy Body

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sacituzumab tirumotecanBiological

    Also called Sac-TMT, MK-2870

    IV infusion

  • PembrolizumabBiological

    Also called MK-3475, Keytruda®

    IV infusion

  • Rescue MedicationDrug

    Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medications are histamine -1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, or steroid mouthwash (dexamethasone or equivalent).

  • CarboplatinDrug

    Also called Paraplatin

    IV infusion

  • PaclitaxelDrug

    Also called Taxol, Onxol

    IV infusion

  • DoxorubicinDrug

    Also called ADRIAMYCIN®

    IV infusion

  • EpirubicinDrug

    Also called Ellence®

    IV infusion

  • CyclophosphamideDrug

    Also called Cytophosphane

    IV infusion

  • CapecitabineDrug

    Also called Xeloda®

    Oral tablet

  • OlaparibDrug

    Also called LYNPARZA®

    Oral tablet

Study groups in NCT06966700
Study groupRoleWhat they receive
sac-TMTExperimentalParticipants receive sacituzumab tirumotecan intravenously (IV) at a dose of 4 mg/kg every 2 weeks (Q2W) + IV pembrolizumab 200 mg every 3 weeks (Q3W), for 12 weeks; then receive IV pembrolizumab 200 mg Q3W and IV carboplatin area under the curve (AUC) 1.5 + IV paclitaxel 80 mg/m^2 once weekly, for 12 weeks. 3-6 weeks later, participants undergo surgery and optional radiation therapy, and receive IV pembrolizumab 400 mg once every 6 weeks or 200 mg Q3W for up to approximately 28 weeks. Additional adjuvant treatment of physician's choice (TPC) may be administered to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline breast cancer susceptibility gene mutation (gBRCAm) only); capecitabine 1000-1250 mg/m^2 oral twice daily on days 1-14 and 22-35 each cycle for 4 six-week cycles; or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W/Q2W + cyclophosphamide 600 mg/m^2 IV infusion Q3W/Q2W for 4 doses.
Receives: Biological: Sacituzumab tirumotecan; Biological: Pembrolizumab; Drug: Rescue Medication; Drug: Carboplatin; Drug: Paclitaxel; Drug: Doxorubicin; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Capecitabine; Drug: Olaparib
ChemotherapyActive comparatorParticipants receive IV carboplatin AUC 1.5 and paclitaxel 80 mg/m^2 once weekly, alongside pembrolizumab 200 mg Q3W, for 6 weeks; then receive IV pembrolizumab 200 mg Q3W alongside IV cyclophosphamide 600 mg/m^2 Q3W and either doxorubicin 60 mg/m^2 Q3W or epirubicin 90 mg/m^2 Q3W, for up to 12 weeks. 3-6 weeks later, participants undergo surgery and optional radiation therapy, and receive IV pembrolizumab 400 mg once every 6 weeks or 200 mg Q3W for up to approximately 28 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options are olaparib 300 mg oral BID for 1 year (participants with germline breast cancer susceptibility gene mutation (gBRCAm) only); or capecitabine 1000-1250 mg/m^2 oral BID on days 1-14 and 22-35 each cycle for 4 six-week cycles.
Receives: Biological: Pembrolizumab; Drug: Rescue Medication; Drug: Carboplatin; Drug: Paclitaxel; Drug: Doxorubicin; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Capecitabine; Drug: Olaparib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants with Pathological Complete Response (pCR) at the Time of Definitive Surgery

    pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy per current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery.

    Measured: Up to approximately 30 weeks

  2. Event-Free Survival (EFS)

    EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first.

    Measured: Up to approximately 92 months

Secondary outcomes (13)

  1. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Measured: Up to approximately 115 months

  2. Percentage of Participants with pCR with No Ductal Carcinoma in Situ (pCR-no DCIS) at the Time of Definitive Surgery

    pCR-no ductal carcinoma in situ (DCIS) (ypT0 ypN0) is defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy per current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.

    Measured: Up to approximately 30 weeks

  3. Percentage of Participants with pCR at the Time of Definitive Surgery (High-risk, early-stage, TNBC subset)

    pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy per current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery. The pCR will be presented for the subset of participants who enrolled with high-risk, early-stage, TNBC.

    Measured: Up to approximately 30 weeks

  4. Event-Free Survival (EFS) (High-risk, early-stage, TNBC subset)

    EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first. The EFS will be presented for the subset of participants who enrolled with high-risk, early-stage, TNBC.

    Measured: Up to approximately 92 months

  5. Overall Survival (OS) (High-risk, early-stage, TNBC subset)

    OS is defined as the time from randomization to death due to any cause.

    Measured: Up to approximately 115 months

  6. Distant Progression or Distant Recurrence-Free Survival (DPDRFS)

    DPDRFS is defined as the time from randomization to first distant progression or distant recurrence event as assessed by investigator, or death due to any cause, whichever occurs first.

    Measured: Up to approximately 92 months

  7. Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status-Quality of Life Score

    The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to Item 30 (""How would you rate your overall quality of life during the past week?") is scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher value indicates a better level of function. The change from baseline in EORTC QLQ-C30 Item 30 score will be reported.

    Measured: Baseline and up to approximately 3 years

  8. Change from Baseline in EORTC QLQ-C30 Physical Functioning Score

    The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of physical functioning.

    Measured: Baseline and up to approximately 3 years

  9. Change from Baseline in EORTC QLQ-C30 Role Functioning Score

    The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of physical functioning.

    Measured: Baseline and up to approximately 3 years

  10. Change from Baseline in EORTC QLQ-C30 Fatigue Score

    The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their fatigue are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better level of function.

    Measured: Baseline and up to approximately 3 years

  11. Change from Baseline in EORTC QLQ Breast Cancer 42 (BR42) Systemic Therapy Side Effects Score

    The EORTC QLQ-BR42 is a 42-item questionnaire to assess the overall quality of life of breast cancer patients. Participant responses to questions about their systemic therapy side effects are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a lower level of side effects.

    Measured: Baseline and up to approximately 3 years

  12. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Measured: Up to approximately 67 weeks

  13. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Measured: Up to approximately 54 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 May 2025
  2. Study start30 Jun 2025
  3. Primary completion23 Mar 2033 (estimated)
  4. Study completion29 Dec 2034 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
2,400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06966700
Sponsor's protocol ID
2870-032
Other IDs
U1111-1316-7898, 2024-520190-12-00, jRCT2031250231
Status last verified
Oct 2026
First submitted
4 May 2025
Last updated
13 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Publications

  • Schmid P, Cortes J, Hui R, Masuda N, Garrido-Castro AC, Loirat D, Shao ZM, Park YH, Wei J, Beca F, Malhotra U, Harbeck N. TroFuse-032 study design: pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, triple-negative breast cancer or HR-low+/HER2- breast cancer. Future Oncol. 2026 Oct 14:1-11. doi: 10.1080/14796694.2026.2732590. Online ahead of print.

    PubMed 42872715

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in